Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Rocket Pharmaceuticals (RCKTW) Financials

Rocket Pharmaceuticals logo
$0.0088 0.00 (-11.12%)
As of 09:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Rocket Pharmaceuticals

Annual Income Statements for Rocket Pharmaceuticals

This table shows Rocket Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -222 -246 -259
Consolidated Net Income / (Loss)		 -222 -246 -259
Net Income / (Loss) Continuing Operations		 -222 -256 -267
Total Pre-Tax Income 		-222 -256 -267
Total Operating Income		 -224 -260 -273
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Operating Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 224 260 273
Selling, General & Admin Expense		 59 73 102
Research & Development Expense		 165 186 171
Total Other Income / (Expense), net		 2.03 3.41 6.38
Interest Expense		 1.86 1.88 1.89
Interest & Investment Income		 3.89 5.29 8.27
Other Adjustments to Consolidated Net Income / (Loss)		 -0.05 11 8.08
Basic Earnings per Share		 ($3.26) ($2.92) ($2.73)
Weighted Average Basic Shares Outstanding		 68.15M 84.01M 94.81M
Diluted Earnings per Share		 ($3.26) ($2.92) ($2.73)
Weighted Average Diluted Shares Outstanding		 68.15M 84.01M 94.81M
Weighted Average Basic & Diluted Shares Outstanding		 79.35M 90.50M 106.63M

Quarterly Income Statements for Rocket Pharmaceuticals

This table shows Rocket Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -58 -67 -58 -66 -62 -60 -62 -70 -67 -60 -61
Consolidated Net Income / (Loss)		 -58 -67 -58 -66 -62 -60 -62 -70 -67 -60 -61
Net Income / (Loss) Continuing Operations		 -58 -68 -61 -68 -64 -63 -65 -72 -69 -62 -64
Total Pre-Tax Income 		-58 -68 -61 -68 -64 -63 -65 -72 -69 -62 -64
Total Operating Income		 -58 -69 -62 -69 -65 -63 -67 -74 -69 -63 -64
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Operating Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 59 68 62 69 65 63 67 74 69 63 64
Selling, General & Admin Expense		 15 19 16 17 19 22 22 27 27 25 28
Research & Development Expense		 43 50 46 51 47 42 45 46 42 37 36
Total Other Income / (Expense), net		 0.89 1.35 1.44 0.38 1.25 0.34 2.56 1.82 0.86 1.14 0.86
Interest Expense		 0.47 0.47 0.47 0.47 0.47 0.47 0.47 0.47 0.47 0.47 0.47
Interest & Investment Income		 1.35 1.82 1.91 0.85 1.72 0.81 3.03 2.29 1.33 1.62 1.34
Other Adjustments to Consolidated Net Income / (Loss)		 - - 2.42 2.68 2.28 3.28 2.76 2.24 1.85 1.22 2.19
Basic Earnings per Share		 ($0.87) ($0.89) ($0.73) ($0.82) ($0.75) ($0.62) ($0.66) ($0.74) ($0.71) ($0.62) ($0.56)
Weighted Average Basic Shares Outstanding		 66.22M 68.15M 79.45M 80.47M 82.64M 84.01M 93.55M 93.75M 94.16M 94.81M 110.09M
Diluted Earnings per Share		 ($0.87) ($0.89) ($0.73) ($0.82) ($0.75) ($0.62) ($0.66) ($0.74) ($0.71) ($0.62) ($0.56)
Weighted Average Diluted Shares Outstanding		 66.22M 68.15M 79.45M 80.47M 82.64M 84.01M 93.55M 93.75M 94.16M 94.81M 110.09M
Weighted Average Basic & Diluted Shares Outstanding		 75.68M 79.35M 80.46M 80.53M 90.16M 90.50M 90.78M 90.98M 91.16M 106.63M 107.74M

Annual Cash Flow Statements for Rocket Pharmaceuticals

This table details how cash moves in and out of Rocket Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -92 -85 108
Net Cash From Operating Activities		 -178 -195 -210
Net Cash From Continuing Operating Activities		 -178 -195 -210
Net Income / (Loss) Continuing Operations		 -222 -246 -259
Consolidated Net Income / (Loss)		 -222 -246 -259
Depreciation Expense		 3.93 4.94 7.22
Amortization Expense		 2.33 -8.01 -5.91
Non-Cash Adjustments To Reconcile Net Income		 32 40 46
Changes in Operating Assets and Liabilities, net		 6.02 14 1.74
Net Cash From Investing Activities		 -69 -98 132
Net Cash From Continuing Investing Activities		 -69 -98 132
Purchase of Property, Plant & Equipment		 -8.36 -16 -5.86
Purchase of Investments		 -376 -391 -246
Sale of Property, Plant & Equipment		 0.00 0.00 0.14
Divestitures		 43 0.00 0.00
Sale and/or Maturity of Investments		 273 309 383
Other Investing Activities, net		 -0.26 -0.04 0.00
Net Cash From Financing Activities		 155 208 186
Net Cash From Continuing Financing Activities		 155 208 186
Repurchase of Common Equity		 -0.05 0.00 0.00
Issuance of Common Equity		 155 206 183
Other Financing Activities, net		 0.63 2.24 3.21
Cash Interest Paid		 0.00 0.00 0.00

Quarterly Cash Flow Statements for Rocket Pharmaceuticals

This table details how cash moves in and out of Rocket Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 9.13 -56 -76 -19 181 -170 -21 3.33 27 98 -114
Net Cash From Operating Activities		 -44 -56 -58 -51 -57 -29 -57 -54 -52 -47 -56
Net Cash From Continuing Operating Activities		 -44 -56 -58 -51 -57 -29 -57 -54 -52 -47 -56
Net Income / (Loss) Continuing Operations		 -58 -67 -58 -66 -62 -60 -62 -70 -67 -60 -61
Consolidated Net Income / (Loss)		 -58 -67 -58 -66 -62 -60 -62 -70 -67 -60 -61
Depreciation Expense		 1.09 1.05 1.14 1.19 1.22 1.40 1.72 1.83 1.85 1.82 2.45
Amortization Expense		 0.69 -0.40 0.54 -4.29 5.37 -9.63 0.54 -4.46 -1.31 -0.68 0.54
Non-Cash Adjustments To Reconcile Net Income		 7.11 10 6.61 13 4.14 17 7.53 14 11 13 8.27
Changes in Operating Assets and Liabilities, net		 4.41 0.16 -7.60 5.30 -6.00 22 -4.59 4.30 2.78 -0.75 -5.73
Net Cash From Investing Activities		 23 -109 -37 31 48 -141 35 56 79 -38 -58
Net Cash From Continuing Investing Activities		 23 -109 -37 31 48 -141 35 56 79 -38 -58
Purchase of Property, Plant & Equipment		 -0.50 -3.00 -3.02 -4.12 -4.66 -4.65 -2.04 -1.93 -1.59 -0.31 -0.36
Purchase of Investments		 -34 -199 -96 -73 -13 -209 -64 -39 -19 -124 -140
Sale and/or Maturity of Investments		 58 51 62 108 66 72 101 96 100 86 82
Other Investing Activities, net		 - -0.26 -0.01 -0.03 - - 0.00 - - - 0.00
Net Cash From Financing Activities		 30 108 18 0.18 189 0.39 1.18 1.53 0.18 183 0.00
Net Cash From Continuing Financing Activities		 30 108 18 0.18 189 0.39 1.18 1.53 0.18 183 0.00
Issuance of Common Equity		 29 108 17 - 189 0.00 0.00 - - 183 0.00
Other Financing Activities, net		 0.23 0.32 1.12 0.18 0.55 0.39 1.18 1.53 0.18 0.32 0.00

Annual Balance Sheets for Rocket Pharmaceuticals

This table presents Rocket Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 552 566 528
Total Current Assets		 364 378 378
Cash & Equivalents		 141 56 164
Short-Term Investments		 216 317 209
Prepaid Expenses		 7.67 5.05 5.85
Plant, Property, & Equipment, net		 29 39 37
Total Noncurrent Assets		 159 148 113
Long-Term Investments		 43 34 0.00
Noncurrent Note & Lease Receivables		 47 45 42
Goodwill		 39 39 39
Intangible Assets		 26 25 25
Other Noncurrent Operating Assets		 3.92 4.43 6.06
Total Liabilities & Shareholders' Equity		 552 566 528
Total Liabilities		 62 74 64
Total Current Liabilities		 39 49 41
Accounts Payable		 37 46 38
Other Current Liabilities		 2.51 2.72 2.86
Total Noncurrent Liabilities		 23 25 24
Other Noncurrent Operating Liabilities		 23 25 24
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 490 493 463
Total Preferred & Common Equity		 490 493 463
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 490 493 463
Common Stock		 1,204 1,452 1,681
Retained Earnings		 -714 -959 -1,218
Treasury Stock		 -0.05 0.00 0.00
Accumulated Other Comprehensive Income / (Loss)		 -0.36 0.32 0.07

Quarterly Balance Sheets for Rocket Pharmaceuticals

This table presents Rocket Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 417 515 462 599 499 446 394 471
Total Current Assets		 311 338 312 447 345 293 242 324
Cash & Equivalents		 197 65 45 226 35 39 66 50
Short-Term Investments		 110 267 262 212 295 240 170 268
Prepaid Expenses		 4.60 6.95 5.03 9.69 15 14 6.09 6.33
Plant, Property, & Equipment, net		 26 31 33 37 39 40 39 35
Total Noncurrent Assets		 81 146 117 115 115 114 113 112
Noncurrent Note & Lease Receivables		 47 46 46 45 44 43 43 42
Goodwill		 31 39 39 39 39 39 39 39
Intangible Assets		 - 26 26 25 25 25 25 25
Other Noncurrent Operating Assets		 2.83 6.17 6.25 6.00 6.66 6.39 6.21 5.88
Total Liabilities & Shareholders' Equity		 417 515 462 599 499 446 394 471
Total Liabilities		 50 56 59 58 58 62 64 59
Total Current Liabilities		 30 31 34 33 33 38 40 35
Accounts Payable		 28 29 31 31 30 35 37 32
Other Current Liabilities		 2.36 2.60 2.99 2.85 2.87 2.86 2.85 2.88
Total Noncurrent Liabilities		 20 25 24 24 25 24 24 24
Other Noncurrent Operating Liabilities		 20 25 24 24 25 24 24 24
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 367 459 403 541 442 385 330 412
Total Preferred & Common Equity		 367 459 403 541 442 385 330 412
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 367 459 403 541 442 385 330 412
Common Stock		 1,015 1,231 1,242 1,441 1,463 1,476 1,487 1,692
Retained Earnings		 -647 -772 -838 -900 -1,021 -1,091 -1,158 -1,279
Accumulated Other Comprehensive Income / (Loss)		 -0.60 -0.09 -0.72 -0.51 -0.14 -0.22 0.21 -0.03

Annual Metrics And Ratios for Rocket Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Rocket Pharmaceuticals' official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 -37.82% -20.48% -3.49%
EBIT Growth		 -34.14% -15.74% -5.22%
NOPAT Growth		 -34.14% -15.74% -5.22%
Net Income Growth		 -31.23% -10.70% -5.35%
EPS Growth		 -22.10% 10.43% 6.51%
Operating Cash Flow Growth		 -47.03% -9.42% -7.60%
Free Cash Flow Firm Growth		 -48.04% 3.10% -13.10%
Invested Capital Growth		 36.42% -7.01% 8.59%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -16.06% -1.24% 3.53%
EBIT Q/Q Growth		 -12.40% 2.19% 0.21%
NOPAT Q/Q Growth		 -12.40% 2.19% 0.21%
Net Income Q/Q Growth		 -11.27% 2.80% -0.26%
EPS Q/Q Growth		 -6.89% 8.46% 0.00%
Operating Cash Flow Q/Q Growth		 -16.39% 12.04% -9.16%
Free Cash Flow Firm Q/Q Growth		 -32.85% 23.37% -9.12%
Invested Capital Q/Q Growth		 48.10% -19.45% -3.41%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 99.80% 95.84% 96.97%
Interest Burden Percent		 99.10% 98.69% 97.66%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -46.98% -50.01% -54.14%
Cash Return on Invested Capital (CROIC)		 -232.14% -201.99% -227.30%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -46.98% -50.01% -54.14%
Return on Equity Simple (ROE_SIMPLE)		 -45.31% -49.86% -55.86%
Net Operating Profit after Tax (NOPAT)		 -157 -182 -191
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -16.44% -15.79% -17.28%
Return On Investment Capital (ROIC_SIMPLE)		 -32.07% -36.90% -41.28%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -224 -260 -273
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -218 -263 -272
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 3.02 5.49 2.47
Price to Tangible Book Value (P/TBV)		 3.49 6.31 2.87
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 12.01 27.41 8.51
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -0.83 -0.82 -0.82
Leverage Ratio		 1.11 1.14 1.14
Compound Leverage Factor		 1.10 1.12 1.12
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 11.86 18.79 6.49
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 9.29 7.80 9.30
Quick Ratio		 9.10 7.69 9.15
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -181 -175 -198
Operating Cash Flow to CapEx		 -2,131.40% -1,185.91% -3,662.02%
Free Cash Flow to Firm to Interest Expense		 -97.25 -93.57 -105.21
Operating Cash Flow to Interest Expense		 -95.67 -103.96 -111.20
Operating Cash Flow Less CapEx to Interest Expense		 -100.16 -112.72 -114.24
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 90 84 91
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 24 -6.31 7.19
Enterprise Value (EV)		 1,081 2,295 774
Market Capitalization		 1,481 2,702 1,146
Book Value per Share		 $6.47 $5.46 $5.08
Tangible Book Value per Share		 $5.61 $4.75 $4.38
Total Capital		 490 493 463
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -400 -407 -372
Capital Expenditures (CapEx)		 8.36 16 5.73
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -32 -43 -35
Debt-free Net Working Capital (DFNWC)		 325 330 337
Net Working Capital (NWC)		 325 330 337
Net Nonoperating Expense (NNE)		 65 64 68
Net Nonoperating Obligations (NNO)		 -400 -409 -372
Total Depreciation and Amortization (D&A)		 6.27 -3.07 1.31
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($3.26) ($2.92) ($2.73)
Adjusted Weighted Average Basic Shares Outstanding		 68.15M 84.01M 94.81M
Adjusted Diluted Earnings per Share		 ($3.26) ($2.92) ($2.73)
Adjusted Weighted Average Diluted Shares Outstanding		 68.15M 84.01M 94.81M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 79.35M 90.50M 106.63M
Normalized Net Operating Profit after Tax (NOPAT)		 -157 -182 -191
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 -120.49 -138.48 -144.86
NOPAT to Interest Expense		 -84.34 -96.94 -101.40
EBIT Less CapEx to Interest Expense		 -124.97 -147.25 -147.90
NOPAT Less CapEx to Interest Expense		 -88.83 -105.71 -104.44
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.02% 0.00% 0.00%

Quarterly Metrics And Ratios for Rocket Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Rocket Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -16.24% -78.87% -48.76% -37.54% -3.75% -4.50% -7.60% -6.23% -17.07% 13.92% 9.54%
EBIT Growth		 -17.81% -55.83% -46.12% -26.83% -11.87% 8.40% -8.33% -7.21% -6.11% 0.92% 4.43%
NOPAT Growth		 -17.81% -55.83% -46.12% -26.83% -11.87% 8.40% -8.33% -7.21% -6.11% 0.92% 4.43%
Net Income Growth		 -15.24% -50.80% -35.72% -20.77% -7.17% 10.59% -6.38% -6.00% -7.79% -1.12% 1.16%
EPS Growth		 -10.13% -30.88% -8.96% 1.20% 13.79% 30.34% 9.59% 9.76% 5.33% 0.00% 15.15%
Operating Cash Flow Growth		 -59.99% -81.06% -46.75% -30.30% -30.30% 47.63% 1.22% -5.81% 8.83% -60.00% 1.87%
Free Cash Flow Firm Growth		 3.55% -99.55% -52.95% -112.58% -137.03% 47.52% 16.58% 20.91% 56.38% -34.46% 53.20%
Invested Capital Growth		 -5.33% 36.42% 39.15% 44.63% 70.97% -7.01% 12.50% 10.30% -9.44% 8.59% -15.48%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -8.55% -20.67% 11.39% -18.73% 18.12% -21.54% -1.06% -17.22% 9.76% 10.64% 0.26%
EBIT Q/Q Growth		 -7.89% -18.11% 9.97% -10.55% 4.84% 3.29% -6.47% -9.41% 5.82% 9.69% -2.70%
NOPAT Q/Q Growth		 -7.89% -18.11% 9.97% -10.55% 4.84% 3.29% -6.47% -9.41% 5.82% 9.69% -2.70%
Net Income Q/Q Growth		 -6.17% -15.53% 12.57% -12.63% 5.79% 3.62% -4.01% -12.23% 4.20% 9.58% -1.67%
EPS Q/Q Growth		 -4.82% -2.30% 17.98% -12.33% 8.54% 17.33% -6.45% -12.12% 4.05% 12.68% 9.68%
Operating Cash Flow Q/Q Growth		 -12.35% -27.73% -2.75% 11.62% -12.34% 48.66% -93.79% 5.33% 3.20% 9.91% -18.85%
Free Cash Flow Firm Q/Q Growth		 -2.61% -92.93% 1.44% -8.95% -14.41% 57.29% -51.22% -3.30% 36.90% -31.67% 45.46%
Invested Capital Q/Q Growth		 -8.37% 48.10% 9.80% -2.94% 8.32% -19.45% 30.69% -4.84% -11.06% -3.41% 3.38%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.27% 98.52% 96.02% 96.08% 96.45% 94.80% 95.74% 96.88% 97.30% 98.01% 96.55%
Interest Burden Percent		 98.48% 98.04% 97.68% 99.45% 98.09% 99.46% 96.20% 97.53% 98.77% 98.18% 98.66%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -46.75% -46.98% -54.13% -62.86% -55.63% -50.01% -55.38% -64.31% -59.27% -54.14% -60.45%
Cash Return on Invested Capital (CROIC)		 -218.11% -232.14% -233.82% -259.54% -278.04% -201.99% -188.30% -197.02% -183.66% -227.30% -167.61%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -46.75% -46.98% -54.13% -62.86% -55.63% -50.01% -55.38% -64.31% -59.27% -54.14% -60.45%
Return on Equity Simple (ROE_SIMPLE)		 -54.28% 0.00% -51.70% -61.67% -46.69% 0.00% -56.47% -65.84% -78.26% 0.00% -62.61%
Net Operating Profit after Tax (NOPAT)		 -41 -48 -44 -48 -46 -44 -47 -52 -49 -44 -45
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.62% -4.66% -4.19% -5.59% -4.33% -3.80% -4.31% -6.16% -5.39% -4.21% -5.02%
Return On Investment Capital (ROIC_SIMPLE)		 - -9.88% - - - -8.99% - - - -9.47% -10.94%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -58 -69 -62 -69 -65 -63 -67 -74 -69 -63 -64
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -57 -68 -61 -72 -59 -72 -65 -76 -69 -62 -61
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.87 3.02 2.96 3.97 3.05 5.49 5.50 5.08 5.10 2.47 1.73
Price to Tangible Book Value (P/TBV)		 3.13 3.49 3.45 4.73 3.46 6.31 6.44 6.10 6.33 2.87 2.04
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 12.30 12.01 10.11 13.47 11.67 27.41 18.87 15.84 15.35 8.51 4.18
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.85 -0.83 -0.81 -0.79 -0.82 -0.82 -0.77 -0.74 -0.77 -0.82 -0.76
Leverage Ratio		 1.11 1.11 1.11 1.13 1.12 1.14 1.13 1.15 1.14 1.14 1.14
Compound Leverage Factor		 1.09 1.09 1.09 1.12 1.10 1.13 1.08 1.12 1.13 1.12 1.12
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 10.84 12.79 12.81 14.00 15.53 19.94 22.59 15.70 11.69 7.81 3.72
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 10.31 9.29 10.83 9.09 13.35 7.80 10.47 7.79 6.05 9.30 9.19
Quick Ratio		 10.16 9.10 10.61 8.94 13.06 7.69 10.02 7.42 5.89 9.15 9.01
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -38 -72 -71 -78 -89 -38 -60 -61 -39 -51 -28
Operating Cash Flow to CapEx		 -8,719.48% -1,865.50% -1,909.12% -1,234.98% -1,227.67% -631.35% -2,793.91% -2,788.76% -3,281.05% -15,191.59% -15,326.92%
Free Cash Flow to Firm to Interest Expense		 -80.69 -154.68 -152.44 -166.09 -189.63 -80.82 -126.36 -130.53 -82.36 -107.98 -59.02
Operating Cash Flow to Interest Expense		 -94.32 -119.70 -122.99 -108.69 -121.85 -62.42 -120.71 -114.27 -110.62 -99.24 -118.20
Operating Cash Flow Less CapEx to Interest Expense		 -95.40 -126.12 -129.43 -117.50 -131.78 -72.31 -125.03 -118.37 -113.99 -99.90 -118.97
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 61 90 99 96 104 84 111 106 94 91 94
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -3.42 24 28 30 43 -6.31 12 9.88 -9.81 7.19 -17
Enterprise Value (EV)		 748 1,081 999 1,292 1,213 2,295 2,099 1,676 1,445 774 393
Market Capitalization		 1,054 1,481 1,359 1,599 1,650 2,702 2,429 1,955 1,680 1,146 711
Book Value per Share		 $5.56 $6.47 $5.78 $5.01 $6.72 $5.46 $4.72 $4.24 $3.62 $5.08 $3.87
Tangible Book Value per Share		 $5.10 $5.61 $4.97 $4.20 $5.92 $4.75 $4.03 $3.53 $2.92 $4.38 $3.26
Total Capital		 367 490 459 403 541 493 442 385 330 463 412
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -307 -400 -360 -307 -437 -407 -330 -279 -236 -372 -318
Capital Expenditures (CapEx)		 0.50 3.00 3.02 4.12 4.66 4.65 2.04 1.93 1.59 0.31 0.36
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -26 -32 -24 -29 -24 -43 -18 -24 -34 -35 -29
Debt-free Net Working Capital (DFNWC)		 281 325 307 278 413 330 312 255 202 337 289
Net Working Capital (NWC)		 281 325 307 278 413 330 312 255 202 337 289
Net Nonoperating Expense (NNE)		 17 18 15 18 16 15 15 18 18 16 16
Net Nonoperating Obligations (NNO)		 -307 -400 -360 -307 -437 -409 -330 -279 -236 -372 -318
Total Depreciation and Amortization (D&A)		 1.78 0.65 1.67 -3.10 6.59 -8.23 2.25 -2.63 0.54 1.14 2.99
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.87) ($0.89) ($0.73) ($0.82) ($0.75) ($0.62) ($0.66) ($0.74) ($0.71) ($0.62) ($0.56)
Adjusted Weighted Average Basic Shares Outstanding		 66.22M 68.15M 79.45M 80.47M 82.64M 84.01M 93.55M 93.75M 94.16M 94.81M 110.09M
Adjusted Diluted Earnings per Share		 ($0.87) ($0.89) ($0.73) ($0.82) ($0.75) ($0.62) ($0.66) ($0.74) ($0.71) ($0.62) ($0.56)
Adjusted Weighted Average Diluted Shares Outstanding		 66.22M 68.15M 79.45M 80.47M 82.64M 84.01M 93.55M 93.75M 94.16M 94.81M 110.09M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 75.68M 79.35M 80.46M 80.53M 90.16M 90.50M 90.78M 90.98M 91.16M 106.63M 107.74M
Normalized Net Operating Profit after Tax (NOPAT)		 -41 -48 -44 -48 -46 -44 -47 -52 -49 -44 -45
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -125.78 -147.61 -132.89 -146.92 -139.51 -134.64 -143.05 -156.50 -147.40 -132.55 -136.42
NOPAT to Interest Expense		 -88.05 -103.33 -93.03 -102.84 -97.66 -94.25 -100.13 -109.55 -103.18 -92.78 -95.49
EBIT Less CapEx to Interest Expense		 -126.86 -154.03 -139.34 -155.72 -149.43 -144.52 -147.37 -160.60 -150.77 -133.20 -137.19
NOPAT Less CapEx to Interest Expense		 -89.13 -109.74 -99.47 -111.64 -107.58 -104.13 -104.45 -113.65 -106.55 -93.44 -96.26
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Rocket Pharmaceuticals (NASDAQ:RCKT) has shown little to no revenue over the last four years, while continuing to incur multi‑million dollar quarterly losses. The company has increasingly relied on equity financings to fund operations, and its balance sheet reflects a substantial common equity base that has grown primarily through new issuances. Cash flow has been volatile, with notable financings and some investment sales helping liquidity in certain quarters, but operating cash burn remains sizable. The following points summarize key trends across the latest four years of quarterly statements.

  • Q4 2024 equity financing: Issuance of Common Equity was about $182.5 million, contributing to a substantial cash infusion. This aligns with a large positive financing cash flow in that quarter (+$182.8 million) and supported a material net increase in cash (+$98.0 million) for the period.
  • Significant financing activity in other periods: In addition to Q4 2024, prior quarters also show meaningful equity financing events (for example, issuance of common equity of about $188.9 million in Q4 2023), underscoring the company’s reliance on equity markets to fund operations.
  • Liquidity from asset maturities: Sale and/or maturity of investments generated meaningful cash in recent quarters (approximately $99.8 million in Q3 2024 and about $86.5 million in Q4 2024), boosting near-term liquidity.
  • Balance sheet expansion of equity base: Total Common Equity rose to about $412.1 million by Q1 2025, reflecting cumulative equity issuances that increased the company’s capital base.
  • Cash balance and liquidity improved via financing in late 2024: The combination of equity issuance and investment sales helped lift cash resources and contributes to a stronger liquidity position entering 2025.
  • No meaningful product revenue in sight: Operating revenue and total revenue are effectively zero across the latest quarters (including Q1 2025 and throughout 2024–2023), indicating the company has not yet generated product revenue.
  • Asset base supported by cash and investments: As of 2025‑Q1, cash and equivalents stood at about $49.8 million and short-term investments at about $268.4 million, with total current assets of roughly $324.5 million. This liquidity profile is largely driven by cash and investments rather than operating cash flow.
  • Asset growth tied to equity funding: Total assets grew to about $471.1 million by 2025‑Q1, consistent with equity financings increasing the capital base rather than earnings growth.
  • Persistent net losses: Net income (loss) remains negative across quarters, e.g., -$61.33 million in 2025‑Q1, -$60.33 million in 2024‑Q4, -$66.72 million in 2024‑Q3, -$69.65 million in 2024‑Q2, and -$64.82 million in 2024‑Q1. This ongoing profitability gap is a clear negative signal.
  • Material operating cash burn: Net cash from continuing operating activities is consistently negative (approx. -$55.8 million in 2025‑Q1, -$46.96 million in 2024‑Q4, -$52.13 million in 2024‑Q3, -$53.86 million in 2024‑Q2, and -$56.86 million in 2024‑Q1), indicating sustained cash burn.
  • Volatile quarterly cash flow mix: While financing and select investment sales provide occasional liquidity boosts, operating cash burn remains the dominant driver of cash flow, highlighting ongoing liquidity risk without sustained revenue generation.
  • Significant dilution risk: The company’s weighted average shares outstanding are substantial (roughly 93–111 million for recent periods, with basic and diluted counts around 90–111 million). Ongoing equity financings imply continued dilution for existing shareholders.
05/20/26 12:13 AM ETAI Generated. May Contain Errors.

Rocket Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Rocket Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

Rocket Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$258.75 million in 2024, rising from -$221.86 million in 2022. The previous period was -$245.60 million in 2023.

Rocket Pharmaceuticals' total operating income in 2024 was -$273.21 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $273.21 million

Over the last 2 years, Rocket Pharmaceuticals' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

Rocket Pharmaceuticals' total liabilities were at $64.47 million at the end of 2024, a 12.6% decrease from 2023, and a 3.8% increase since 2022.

In the past 2 years, Rocket Pharmaceuticals' cash and equivalents has ranged from $55.90 million in 2023 to $163.64 million in 2024, and is currently $163.64 million as of their latest financial filing in 2024.

Over the last 2 years, Rocket Pharmaceuticals' book value per share changed from 6.47 in 2022 to 5.08 in 2024, a change of -21.5%.


Related Companies

Financial statements for NASDAQ:RCKTW last updated on 5/9/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel